Updating results

Breast cancer (brain metastases) - etirinotecan pegol [ID881]

In development [GID-TA10066] Expected publication date: TBC

Technology appraisal guidance In development

Clostridium difficile associated diarrhoea - tolevamer [ID378]

In development [GID-TAG389] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

In development [GID-TA10148] Expected publication date: TBC

Technology appraisal guidance In development

Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]

In development [GID-TAG369] Expected publication date: TBC

Technology appraisal guidance In development

Head and neck cancer - contusugene ladenovec [ID76]

In development [GID-TAG407] Expected publication date: TBC

Technology appraisal guidance In development

Renal cell carcinoma (second line metastatic) - pazopanib [ID70]

In development [GID-TAG398] Expected publication date: 01 January 2011

Technology appraisal guidance In development

Pacritinib for treating myelofibrosis [ID880]

In development [GID-TA10133] Expected publication date: TBC

Technology appraisal guidance In development

Osteoarthritis - naproxcinod [ID417]

In development [GID-TAG426] Expected publication date: TBC

Technology appraisal guidance In development

Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

In development [GID-TA10154] Expected publication date: TBC

Technology appraisal guidance In development

Kidney transplantation (rejection) - belatacept [ID87]

In development [GID-TAG239] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism - apixaban (acute medical illness) [ID310]

In development [GID-TAG419] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

In development [GID-TAG496] Expected publication date: TBC

Technology appraisal guidance In development

Hypercholesterolemia - mipomersen [ID524]

In development [GID-TAG437] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]

In development [GID-TAG404] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small cell) - afatinib [ID357]

In development [GID-TAG422] Expected publication date: TBC

Technology appraisal guidance In development

Thrombophilia [ID393]

In development [GID-TAG374] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]

In development [GID-TA10158] Expected publication date: TBC

Technology appraisal guidance In development

Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

In development [GID-TAG332] Expected publication date: TBC

Technology appraisal guidance In development

Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]

In development [GID-TA10026] Expected publication date: TBC

Technology appraisal guidance In development

Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

In development [GID-TA10337] Expected publication date: 19 February 2020

Technology appraisal guidance In development

Diabetic foot infection: antimicrobial prescribing

In development [GID-NG10132] Expected publication date: 11 October 2019

Antimicrobial prescribing guideline In development

Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 10 November 2020

Antimicrobial prescribing guideline In development

Nivolumab with radiation therapy for untreated glioblastoma ID1562

In development [GID-TA10443] Expected publication date: TBC

Technology appraisal guidance In development

Veliparib with carboplatin and paclitaxel for untreated epithelial ovarian, fallopian tube or primary peritoneal cancer ID1561

In development [GID-TA10442] Expected publication date: TBC

Technology appraisal guidance In development

Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer [ID1412]

In development [GID-TA10398] Expected publication date: 09 December 2020

Technology appraisal guidance In development

Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]

In development [GID-TA10399] Expected publication date: TBC

Technology appraisal guidance In development

Daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable ID1492

In development [GID-TA10441] Expected publication date: TBC

Technology appraisal guidance In development

Andexanet alfa for reversing anticoagulation [ID1101]

In development [GID-TA10440] Expected publication date: 10 June 2020

Technology appraisal guidance In development

Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172

In development [GID-TA10394] Expected publication date: TBC

Technology appraisal guidance In development

Naldemedine for treating opioid-induced constipation ID1189

In development [GID-TA10291] Expected publication date: 05 June 2020

Technology appraisal guidance In development

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Technology appraisal guidance In development

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Sapropterin for treating phenylketonuria [ID1475]

In development [GID-TA10378] Expected publication date: TBC

Technology appraisal guidance In development

Lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies ID1444

In development [GID-TA10477] Expected publication date: TBC

Technology appraisal guidance In development

ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

In development [GID-TA10489] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

In development [GID-TA10277] Expected publication date: TBC

Technology appraisal guidance In development

Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

In development [GID-TA10377] Expected publication date: TBC

Technology appraisal guidance In development

Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455

In development [GID-TA10356] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for untreated advanced gastric cancer [ID1465]

In development [GID-TA10352] Expected publication date: 14 July 2021

Technology appraisal guidance In development

Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

In development [GID-TA10353] Expected publication date: TBC

Technology appraisal guidance In development

Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

In development [GID-TA10363] Expected publication date: TBC

Technology appraisal guidance In development

Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]

In development [GID-TA10361] Expected publication date: TBC

Technology appraisal guidance In development

Lenalidomide for untreated follicular lymphoma ID1245

In development [GID-TA10308] Expected publication date: TBC

Technology appraisal guidance In development

Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (ID1375)

In development [GID-TA10360] Expected publication date: TBC

Technology appraisal guidance In development

Nintedanib for untreated malignant pleural mesothelioma (ID1424)

In development [GID-TA10359] Expected publication date: TBC

Technology appraisal guidance In development

Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

In development [GID-TA10326] Expected publication date: TBC

Technology appraisal guidance In development

Guadecitabine for untreated acute myeloid leukaemia ID1411

In development [GID-TA10325] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335

In development [GID-TA10315] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355

In development [GID-TA10321] Expected publication date: TBC

Technology appraisal guidance In development

Lurbinectidin for treating advanced platinum-resistant ovarian cancer ID1340

In development [GID-TA10313] Expected publication date: TBC

Technology appraisal guidance In development